While drugmaker Merck & Co. announced Thursday it would be cutting back the prices on some of its drugs, none of its major, top-selling cancer and diabetes treatments will see any lower costs, the New York Times reports.
Among the drugs receiving price cuts, Zepatier, a hepatitis C drug, will see a 60 percent cut in its list price. According to the Times, the drugmaker posted no sales for the drug in Q1 of 2018.
The other drugs receiving a discount have reportedly lost patent protections, and generic versions are already offered at lower costs.
Merck in a statement said it was pulling back prices in a bid to deliver lower out-of-pocket costs to patients, according to the Times.
Click here to read the full report on the New York Times. (Paid subscription required after five articles)